Pardes Biosciences (NASDAQ:PRDS) Cut to Market Perform at JMP Securities theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Pardes Biosciences (NASDAQ:PRDS – Get Free Report) and Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Earnings and Valuation This table compares Pardes […]
Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Free Report) was the target of a large drop in short interest in June. As of June 30th, there was short interest totalling 1,120,000 shares, a drop of 45.1% from the June 15th total of 2,040,000 shares. Based on an average daily trading volume, of 219,200 shares, the days-to-cover […]
BML Capital Management LLC purchased a new stake in shares of Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,867,984 shares of the company’s stock, valued at approximately $8,227,000. Pardes Biosciences makes up approximately 7.9% of […]
Foresite Capital Management V LLC increased its stake in Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,037,935 shares of the company’s stock after purchasing an additional 637,420 shares during the period. Pardes […]